TRACON PHARMACEUTICALS, INC. SEVERANCE PLAN SEVERANCE AGREEMENTSeverance Agreement • March 1st, 2019 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Severance Agreement (the “Agreement”) is entered into effective May 29, 2018 (the “Effective Date”), by and between Mark Wiggins (“you” or “your”) and TRACON Pharmaceuticals, Inc. (the “Company”) pursuant to the TRACON Pharmaceuticals, Inc. Severance Plan (“Plan”). Capitalized terms used herein but not otherwise defined have the meanings set forth in the Plan.
TRACON PHARMACEUTICALS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 1st, 2019 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of February 5, 2019 (the “Effective Date”), by and between TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Charles P. Theuer (the “Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. From and following the Effective Date, this Agreement shall replace and supersede that certain Amended and Restated Employment Agreement between Executive and Company entered into as of February 27, 2017 (the “Prior Agreement”). Certain capitalized terms used in this Agreement are defined in Section 11.
EMPLOYMENT AGREEMENT For MARK WIGGINSEmployment Agreement • March 1st, 2019 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into effective as of May 29, 2018 (the “Effective Date”), by and between TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark Wiggins (the “Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
Amendment One to License and Option AgreementLicense and Option Agreement • March 1st, 2019 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment One to License and Option Agreement (the “Amendment”) is effective as of January 15, 2019 (the “Amendment Effective Date”), by and between Janssen Pharmaceutica N.V. (“Janssen”) and TRACON Pharmaceuticals, Inc., a Delaware corporation (“Licensee”). Each of Janssen and Licensee is sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
